title: Response to letter regarding article, "Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry".
authors.forename: Benjamin
authors.initials: B
authors.lastname: Hibbert
authors.forename: Andrea
authors.initials: A
authors.lastname: MacDougall
authors.forename: Melissa
authors.initials: M
authors.lastname: Blondeau
authors.forename: Edward R
authors.initials: ER
authors.lastname: O'Brien
authors.forename: Derek Y F
authors.initials: DY
authors.lastname: So
authors.forename: Marino
authors.initials: M
authors.lastname: Labinaz
authors.forename: Alexander
authors.initials: A
authors.lastname: Dick
authors.forename: Christopher
authors.initials: C
authors.lastname: Glover
authors.forename: Michael
authors.initials: M
authors.lastname: Froeschl
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Marquis
authors.forename: George A
authors.initials: GA
authors.lastname: Wells
authors.forename: Michel R
authors.initials: MR
authors.lastname: Le May
mesh_terms: D000991:Antithrombins / Q000627:therapeutic use*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000628:therapy*; D010446:Peptide Fragments / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention
chemical_list: D000991:Antithrombins; D005343:Fibrinolytic Agents; D010446:Peptide Fragments